featured
Cabozantinib Effective as Salvage Therapy in TKI-Refractory Differentiated Thyroid Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Cabozantinib as Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial
J. Clin. Oncol 2017 Aug 17;[EPub Ahead of Print], ME Cabanillas, JA de Souza, S Geyer, LJ Wirth, ME Menefee, SV Liu, K Shah, J Wright, MH ShahFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.